Amgen (NASDAQ:AMGN – Get Rating) was downgraded by equities researchers at Barclays from an “equal weight” rating to an “underweight” rating in a research report issued on Monday, MarketBeat Ratings reports. They currently have a $234.00 target price on the medical research company’s stock. Barclays‘s price target indicates a potential downside of 13.99% from the […]
Related Keywords
Canada ,R Sanders Williams ,Robert Eckert ,Piper Sandler ,Robertw Baird ,Amgen ,Securities Exchange Commission ,Asset Dedication ,Quilter Plc ,Indexiq Advisors ,Group Ltd ,Advisor Group ,Amgen Inc ,Barclays ,Royal Bank ,Get Rating ,Marketbeat Ratings ,Director Robert Eckert ,Exchange Commission ,Directorr Sanders Williams ,Amgen Daily ,Nasdaq Amgn ,Amgn ,Medical ,03116210 ,Downgrade ,Barclays Plc ,
comparemela.com © 2020. All Rights Reserved.